Prostazen NDC 80353-702

NDC codes

FDA NDC Directory

Product NDC (as listed)80353-702Labeler and product segments. Claims need a package NDC.

Product NDC at billing width80353-0702Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
80353-702-01	80353070201	1 BOTTLE in 1 BOX (80353-702-01) / 1 CAPSULE in 1 BOTTLE (80353-702-02) / 60 CAPSULE in 1 CAPSULE (80353-702-03)Marketed from Jan 12, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Prostazen
Generic name (nonproprietary): enlarged prostate, prostatic utricle function, and prostatitis recovery
Active ingredients: Saw palmetto — 1 [hp_X]/1Rubia cordifolia root — 1 [hp_X]/1Reynoutria japonica root — 1 [hp_X]/1
Dosage form: Capsule
Route: Oral
Labeler: HCBIOPHARM LLC
Product type: Over-the-counter drug
Marketing category: Unapproved homeopathic
Marketing start: Jan 12, 2022
Listing expires: Dec 31, 2027
Identifiers: Product ID 80353-702_4e38e5b2-1fc2-dfcb-e063-6294a90a3dc8SPL ID 4e38e5b2-1fc2-dfcb-e063-6294a90a3dc8SPL set ID d16bc0cb-b9a6-9a24-e053-2995a90a7cd4UNII J7WWH9M8QS, 4V873H15CG, 7TRV45YZF7

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N480353070201 followed by a unit qualifier and the quantity

Package 80353-0702-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 30, 2026.

Indications (excerpt from the label)

Use To reverse enlarged prostate To restore prostatic utricle function To reverse prostatitis

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)